Experimental vaccine protects against C. diff disease and recurrence
Medical Xpress
February 18, 2026
A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine administered to the mucosal lining of the colon protected against illness, death, tissue damage and infection recurrence. The findings, reported Feb. 18 in the journal Nature, represent a major step forward for vaccine development for C. diff, the leading cause of health care- and antibiotic-associated infection.
Verticals
healthmedical
Originally published on Medical Xpress on 2/18/2026